Trial: 202009029

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigators Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)

Phase

III

Principal Investigator

Bagegni, Nusayba

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov